[{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inteligex","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Exosome-based Therapy","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery Platform","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Inteligex","highestDevelopmentStatusID":"3","companyTruncated":"NurExone Biologic \/ Inteligex"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The collaboration aims to combine Inteligex’s two decades of cell therapy expertise with NurExone’s exosome platform to treat chronic spinal cord injuries.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 17, 2024

                          Lead Product(s) : Exosome-based Therapy

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Discovery Platform

                          Sponsor : Inteligex

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank